Trial reportAntimicrobial agents and chemotherapy2022
Early Bactericidal Activity of Delpazolid (LCB01-0371) in Patients with Pulmonary Tuberculosis.
Open access · hybridAbstract readRandomized Controlled Trial
In one paragraph
Trial report in Antimicrobial agents and chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.6field-weighted citation impact, top 13% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 38 citations in OpenAlex.
- Preclinical and clinical evaluation of vancomycin plus delpazolid combination therapy for MRSA bacteremia: a multicenter, double-blinded, randomized, parallel design, phase IIa clinical trial.Microbiology spectrum · 2026Trial
- Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB.The Journal of antimicrobial chemotherapy · 2025Trial
- The Structure, Properties, and Clinical Utility of Contezolid for Antituberculosis: A Narrative Review.Infectious diseases and therapy · 2026Review
- Current and emerging therapies for pulmonary tuberculosis in adults.BMJ medicine · 2026Review
- New drugs for the management of tuberculosis.Current opinion in infectious diseases · 2025Review
- Bridging science and policy in tuberculosis treatment through innovations in precision medicine, drug development, and cohort research: a narrative review.Ewha medical journal · 2025Review
- Activity of combinations of bactericidal and bacteriostatic compounds inFrontiers in microbiology · 2025Review
- Contezolid Harbored Equivalent Efficacy to Linezolid in Tuberculosis Treatment in a Prospective and Randomized Early Bactericidal Activity Study.Infection and drug resistance · 2025Article
- New Oxazolidinones for Tuberculosis: Are Novel Treatments on the Horizon?Pharmaceutics · 2024Review
- Therapeutic developments for tuberculosis and nontuberculous mycobacterial lung disease.Nature reviews. Drug discovery · 2024Review
- Identification and optimization of pyridine carboxamide-based scaffold as a drug lead forAntimicrobial agents and chemotherapy · 2024Article
- In Vitro Activities of Oxazolidinone Antibiotics Alone and in Combination with C-TEMPO against Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2023Article
- Intracellular and in vivo activities of oxazolidinone drugs against Mycobacterium avium complex infection.Scientific reports · 2023Article
- Advances in Diagnostics and Drug Discovery against Resistant and Latent Tuberculosis Infection.Pharmaceutics · 2023Review
- Staph wars: the antibiotic pipeline strikes back.Microbiology (Reading, England) · 2023Review
- Antibiotics in the clinical pipeline as of December 2022.The Journal of antibiotics · 2023Review
- Chiral Separation of Oxazolidinone Analogs by Capillary Electrophoresis Using Anionic Cyclodextrins as Chiral Selectors: Emphasis on Enantiomer Migration Order.Molecules (Basel, Switzerland) · 2023Review
- Side-by-Side Profiling of Oxazolidinones to Estimate the Therapeutic Window against Mycobacterial Infections.Antimicrobial agents and chemotherapy · 2023Article
- Delphi Survey on the Current and Future Korean Guidelines for Isoniazid-Monoresistant Tuberculosis.Infection and drug resistance · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 15 institutions in 3 countries.
Ju Sang KimDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
Yong-Hyun KimDivision of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
Sang Haak LeeDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
Yee Hyung KimDepartment of Pulmonary, Allergy and Critical Care Medicine, Kyung Hee University Hospital at Gangdong, Kyung Hee University, Seoul, South Korea.
Jin-Woo KimDivision of Pulmonology and Critical Care Medicine, Department of Internal Medicine, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
Ji Young KangDivision of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
Sung Kyoung KimDivision of Pulmonology, Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, South Korea.
Seung Joon KimDivision of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
Yun-Seong KangDivision of Pulmonology and Critical Care Medicine, Dongguk University Ilsan Hospital, Dongguk University College of Medicine, Goyang, South Korea.
Tae-Hyung KimDepartment of Internal Medicine, Hanyang University College of Medicine, Guri, South Korea.
Jeongha MokDepartment of Internal Medicine, Pusan National University Hospital, Busan, South Korea.
Min Kwang ByunDepartment of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Gangnam-gu, Seoul, South Korea.
Hye Jung ParkDepartment of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Gangnam-gu, Seoul, South Korea.
Joon-Sung JohDepartment of Internal Medicine, National Medical Center, Seoul, South Korea.
Yong Bum ParkDepartment of Internal Medicine, Hallym University Medical Center, Kangdong Sacred Heart Hospital, Seoul, South Korea.
Hyeong-Seok LimDepartment of Clinical Pharmacology and Therapeutics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Hongjo ChoiDepartment of Preventive Medicine, Konyang University College of Medicine, Daejon, South Korea.
Seung Heon LeeThe Korean Institute of Tuberculosis, Cheongju, South Korea.
Hyejin KimThe Korean Institute of Tuberculosis, Cheongju, South Korea.ORCID 0000-0002-7158-4424
Jeongseong YangThe Korean Institute of Tuberculosis, Cheongju, South Korea.
Hyunji KimThe Korean Institute of Tuberculosis, Cheongju, South Korea.
Xianlin ShenMerlin Clinical Service, Gaithersburg, Maryland, USA.
Abdullah AlsultanClinical Pharmacy, Department College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
InSook ChoLegoChem BioSciences, Seoul, South Korea.
Lawrence GeiterConsultant, Sunny Isles Beach, Florida, USA.
Tae Sun ShimDepartment of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.ORCID 0000-0001-6653-816X
Catholic University of Korea · KRThe Catholic University of Korea Bucheon St. Mary's Hospital · KRThe Catholic University of Korea Incheon St. Mary's Hospital · KRThe Catholic University of Korea St. Vincent's Hospital · KRUlsan College · KRYonsei University · KRDongguk University Ilsan Hospital · KRHanyang University Guri Hospital · KRIsles · USKangdong Sacred Heart Hospital · KRKing Saud University · SAKonyang University · KRNational Medical Center · KRPusan National University Hospital · KRThe Catholic University of Korea Seoul St. Mary's Hospital · KR
Funding
No grant is acknowledged in the PubMed record.
Abstract
Delpazolid, an oxazolidinone, has been studied in non-clinical studies of efficacy and toxicity and Phase 1 clinical studies. Delpazolid has
Indexed as
Mycobacterium tuberculosisOxazolidinonesTuberculosis, PulmonaryAdultAgedAntitubercular AgentsDrug Therapy, CombinationHumansIsoniazidMiddle AgedPyrazinamideSputumYoung AdultAntitubercular AgentsdelpazolidIsoniazidOxazolidinonesPyrazinamideearly bactericidal activityexperimental therapeuticsMycobacterium tuberculosisoxazolidinones
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.